Teclistamab: First Approval

Teclistamab (TECVAYLI ® ), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval in the EU for the treatme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2022-11, Vol.82 (16), p.1613-1619
1. Verfasser:	Kang, Connie
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Adult Agreements Antibodies Antibodies, Bispecific Antigens Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antiviral Agents Bispecific antibodies CD3 antigen CD38 antigen Collaboration Cytotoxicity Drug dosages Humans Immunomodulation Immunotherapy Inhibitors Internal Medicine Lymphocytes Medicine Medicine & Public Health Molecular Targeted Therapy Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Patients Pharmaceuticals Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Proteasome inhibitors Proteasome Inhibitors - pharmacology Proteasome Inhibitors - therapeutic use Proteasomes R&D Research & development Response rates Royalties Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!